AnaptysBio (NASDAQ:ANAB) reported positive topline data from an interim analysis of its Phase 2 trial evaluating imsidolimab or the treatment of generalized pustular psoriasis (GPP). GPP is a rare, chronic, life...
The FDA granted AnaptysBio’s (NASDAQ:ANAB) imsidolimab orphan drug designation for the treatment of generalized pustular psoriasis (GPP). GPP is a rare, chronic, life-threatening disease characterized by the development...
AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...